Vimian Group ABCHIX:VIMIAS 59 OCF Yield % is 7.61 as of Jul. 09, 2026, which is 632% above its 10-year median of 1.04. GuruFocus rates CHIX:VIMIAS with a GF Score™ of 59/100 and a GF Value™ of kr31.92 (Fairly Valued). The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Vimian Group AB ranks better than 74.77% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Vimian Group AB's OCF Yield % or its related term are showing as below:
CHIX:VIMIAs'
s OCF Yield % Range Over the Past 10 Years
Min: -4.59 Med: 1.04 Max: 8.7
Current: 7.61
During the past 9 years, the highest OCF Yield % of Vimian Group AB was 8.70%. The lowest was -4.59%. And the median was 1.04%.
CHIX:VIMIAs's OCF Yield % is ranked better than 74.77% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.065
vs CHIX:VIMIAs: 7.61
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vimian Group AB OCF Yield % Related Terms
Vimian Group AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VIMIAS vs TMO, DHR, IDXX: OCF Yield % Comparison
For the Diagnostics & Research subindustry, Vimian Group AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (CHIX:VIMIAS) has a OCF Yield % of 7.61 as of Jul. 09, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vimian Group AB and its competitors. This is 632% above median its historical median of 1.04. According to the industry distribution chart, Vimian Group AB ranks #54 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 25.2%.
Is Vimian Group AB's OCF Yield % too high?
Vimian Group AB's current OCF Yield % of 7.61 is 632% above median its 10-year median of 1.04. The Medical Diagnostics & Research industry median OCF Yield % is 1.07. Vimian Group AB's value of 7.61 is 614.6% above this industry median. Based on the distribution chart, Vimian Group AB ranks #54 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's OCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #54 out of 214 companies for OCF Yield %. This puts Vimian Group AB in the upper half of its industry. The industry median OCF Yield % is 1.07. Vimian Group AB's value of 7.61 is 614.6% above this benchmark. While the company's 10-year median is 1.04 vs. the industry median of 1.07, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.07, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current OCF Yield % of 7.61 is 614.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current OCF Yield % is 7.61, which is 632% above median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Based on GuruFocus' analysis, Vimian Group AB (CHIX:VIMIAS) is currently considered Fairly Valued. The stock's GF Value™ is kr31.92, compared to a current price of kr30.28 — trading 5.2% below its estimated fair value. The current OCF Yield % is 7.61, which is 632% above median its 10-year median of 1.04 and 614.6% above the Medical Diagnostics & Research industry median of 1.07. Vimian Group AB's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Vimian Group AB (CHIX:VIMIAS), the current OCF Yield % is 7.61 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (CHIX:VIMIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of kr30.28 is trading 5.2% below its estimated GF Value™ of kr31.92.
GuruFocus considers Vimian Group AB to be Fairly Valued.
Key valuation signals for CHIX:VIMIAS:
OCF Yield %: 7.61 (632% above median its 10-year median of 1.04)
GF Value™: kr31.92 vs. price of kr30.28 (5.2% below fair value)
Industry Position: 614.6% above the Medical Diagnostics & Research median (#54 of 214)
No single metric tells the full story. See the CHIX:VIMIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
59GF Score
Get the complete analysis for CHIX:VIMIAS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VIMIAS has been successfully added to your 
